Bayer reports positive clinical data for Xarelto

Bayer has announced new clinical data that demonstrates the significant benefits that Xarelto can offer for patients with coronary or peripheral artery disease.

In association with development partner Janssen, the company has presented new data from the phase III COMPASS study at this year's European Society of Cardiology Congress, with findings simultaneously published in the New England Journal of Medicine.

It was shown that the rivaroxaban therapy, when taken alongside aspirin, reduced the risk of stroke, cardiovascular death and heart attack by 24 percent in patients with chronic coronary or peripheral artery disease.

Overall, the regimen demonstrated a substantial improvement in net clinical benefit of 20 percent. Bleeding rates were shown to be low, with no significant increase in intracranial or fatal bleeding.

Dr Joerg Moeller, member of the executive committee of Bayer's pharmaceutical division and head of development, said: "No other novel oral anticoagulant has been studied in this patient population and the magnitude of these results clearly shows the benefit rivaroxaban could bring to patients."

The COMPASS study is the largest clinical study of Xarelto to date, and was stopped approximately one year ahead of schedule due to overwhelming efficacy.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.